New radiation techniques like IMRT, IGRT, and SBRT aim to reduce pneumonitis incidence by minimizing radiation exposure to normal tissues. SHOW MORE Pneumonitis, a lung inflammation, often appears ...

Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival after Stereotactic Body Radiation Therapy for Lung Cancer. Journal of Thoracic Oncology , 2014; 1 DOI: 10. ...

Thus, if the severity of ILD and the risk of radiation pneumonitis are carefully evaluated, SBRT is a curative-intent treatment option for those with early-stage NSCLC and pretreatment ILD." ...

SAN FRANCISCO, March 16, 2017--Patients in their 80s and 90s who have early stage lung cancer but cannot undergo an operation can be treated safely and effectively with stereotactic body radiation ...

Stereotactic body radiation therapy (SBRT) is an alternative to conventional radiotherapy for patients unfit for surgery who have early-stage, peripheral non–small-cell lung cancer. Compared with ...

November 5, 2010 (San Diego, California) — Stereotactic radiation might be an option for patients with operable early-stage nonsmall-cell lung cancer (NSCLC). According to the results of a ...

March 18, 2010 (Washington, DC) — Stereotactic body radiation therapy (SBRT) improved survival and local control in a group of patients with inoperable early-stage lung cancer, according to a ...

Stereotactic body radiation therapy (SBRT) is highly effective, and potentially curable for early-stage lung cancer, though not many physicians use the therapy, says expert Molly Freeman, C.N.P.

Highlights. Surgical removal of the tumor is the most viable option for early stage lung cancer. But the elderly, who cannot tolerate the surgery, can be treated using body radiation therapy (SBRT).

According to a 2019 study in Lancet Oncology, SBRT nearly doubles survival in people with stage 1 lung cancer when compared with standard radiation therapy.. Oligometastases. Oligometastases is ...

Single-fraction stereotactic body radiation therapy appeared safe and effective for patients with up to three oligometastatic lung tumors, according to results of the phase 2 SAFRON II trial ...